Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 627

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 627
---
 the closing of the Business Combination and (iii) 167,337 shares of New Semnur Common Stock issued upon the assumed conversion of the Working Capital Loans in connection with Closing. |

| (10) | The business address of Scilex is 960 San Antonio Road, Palo Alto, CA 94303. |

| (11) | Consists of (i) 200,000,000 shares of New Semnur Common Stock issued as Merger Consideration (which number includes the 5,000,000 shares of Semnur Common Stock contributed to Scilex Bio (which is controlled by Scilex) on April 17, 2025 (which will be converted into 6,250,000 shares of New Semnur Common Stock as Merger Consideration in connection with the Business Combination pursuant to the terms of the Merger Agreement)), (ii) 600,000 shares of New Semnur Common Stock issued as Preferred Consideration and (iii) 18,000 shares of New Semnur Common Stock issued upon the assumed conversion of the Scilex Convertible Note in connection with Closing, which is the maximum number of shares that may be issued upon the conversion of the Scilex Convertible Note. |

| (12) | This information is based solely on a Schedule 13G filed by Mizuho Financial Group, Inc. (“Mizuho”) with the SEC on February 14, 2023. Mizuho has sole voting power of 493,672 shares and sole dispositive power of 493,672 shares. The number of shares held by Mizuho is reported as of December 31, 2022, as stated in the Schedule 13G, which does not reflect any redemption of shares by Mizuho in connection with extensions of the deadlines to complete the Business Combination or the Business Combination itself, or any other transactions after December 31, 2022. The business address of such holder is 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100-8176, Japan. West 55th Street, Suite 30A, New York, New York 10019. |

| (13) | This information is based solely on a Schedule 13G filed by TD Securities (USA) LLC, Cowen Financial Products LLC, TD Group US Holdings LLC, Toronto Dominion Bank and Toronto Dominion Holdings Bank (the “TD Reporting Persons”) with the SEC on December 26,